Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
This study investigates the effects of gastric inhibitory polypeptide (GIP) and glycated GIP (glucitol adduct of GIP) on glucose uptake and metabolism in muscle. Glycated GIP (molecular mass 5147.2 Da) was purified by HPLC following in vitro incubation under hyperglycaemic reducing conditions (24 h at pH 7.4). GIP (10(-10)-10(-8) mol/l) significantly stimulated (1.4- to 1.5-fold, P < 0.001) 2-deoxy-D-[1-3H]glucose uptake in abdominal muscle pieces from 3- to 5-week-old lean mice compared with control incubations (without GIP). This stimulatory effect on glucose uptake at 10(-10)-10(-9) mol/l was decreased by 13-20% following glycation of the peptide (P < 0.05). GIP (10(-9) and 10(-8) mol/l) induced a stepwise 1.4- to 1.7-fold increase (P < 0.01, P < 0.001 respectively) in [14C]glucose oxidation compared with controls. This effect on glucose oxidation was diminished by 32% with 10(-8) mol/l glycated GIP (P < 0.05). GIP (10(-9) and 10(-8) mol/l) induced a 1.4- to 1.8-fold increase in [14C]glucose incorporation into muscle glycogen (glycogenesis) compared with controls. Glycated GIP (10(-8) mol/l) exhibited a 41% decrease in glycogenic activity (P < 0.01). GIP (10(-10)-10(-8) mol/l) stimulated lactate production in isolated abdominal muscle (1.2- to 1.3-fold, P < 0.05); however glycated GIP did not exert a significant effect. This study demonstrates for the first time that GIP promotes glucose uptake, glucose oxidation and glycogenesis in muscle tissue. Furthermore, modification of GIP through glycation diminishes its biological effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“O’Harte et al. showed that GIP enhanced glucose transport in the mouse diaphragm [56].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
HOSKINS, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Comparative biochemistry and physiology
(1975) · Comparative Biochemistry and Physiology Part B: Comparative Biochemistry · doi:10.1016/0305-0491(75)90161-3 · Cited by 779
Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., & Bonner, T. I. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243312 · Cited by 534 · cited 2×
“Receptors for GIP have been described in a number of tissues including human insulinomas (Maletti et al. 1986) as well as in endocrine pancreas, stomach, proximal small intestine, adipose tissue, adrenal gland, brain and pituitary ( Usdin et al. 1993, Moens et al. 1996) but not to our knowledge in skeletal muscle.”
BackgroundFEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528 · cited 1×
“…action of GIP makes a major contribution to its metabolic role, direct effects of GIP at extrapancreatic sites, including stomach, liver and adipose tissue, have been suggested to contribute to the overall action of the hormone on post-prandial nutrient homeostasis (Fehmann et al. 1995).”
BackgroundFurther purification of a polypeptide demonstrating enterogastrone activity
Brown, J. C., Mutt, V., & Pederson, R. A. (1970) · The Journal of Physiology · doi:10.1113/jphysiol.1970.sp009155 · Cited by 276 · cited 2×
“The forty-two amino acid GIP was initially isolated from porcine intestine for its ability to inhibit gastric acid secretion (Brown et al. 1970), but its most important physiological role resides in its insulinotrophic activity (Morgan et al. 1988).”
BackgroundMoens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250 · cited 2×
“Receptors for GIP have been described in a number of tissues including human insulinomas (Maletti et al. 1986) as well as in endocrine pancreas, stomach, proximal small intestine, adipose tissue, adrenal gland, brain and pituitary (Usdin et al. 1993, Moens et al. 1996 ) but not to our knowledge in skeletal muscle.”
BackgroundOral Glucose Augmentation of Insulin Secretion
Andersen, D. K., Elahi, D., Brown, J. C., Tobin, J. D., & Andres, R. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109100 · Cited by 240 · cited 2×
“1995) to stimulate insulin secretion and enhance proinsulin gene expression (Andersen et al. 1978).”
BackgroundGastric Inhibitory Polypeptide (GIP) Stimulation by Oral Glucose in Man
CATALAND, S., CROCKETT, S. E., BROWN, J. C., & MAZZAFERRI, E. L. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-2-223 · Cited by 227 · cited 2×
“Oral glucose is absorbed from the small intestine through an active sodium- dependent transport mechanism resulting in a sharp rise in plasma immunoreactive GIP and insulin concentrations (Cataland et al. 1974).”
BackgroundGastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219 · cited 1×
“These include the stimulation of glucose uptake in adipocytes, increased synthesis of fatty acids and activation of lipoprotein lipase in adipose tissue (Eckel et al. 1979, Oben et al. 1991, Morgan 1996).”
BackgroundOben, J., Morgan, L., Fletcher, J., & Marks, V. (1991) · Journal of Endocrinology · doi:10.1677/joe.0.1300267 · Cited by 188 · cited 1×
“These include the stimulation of glucose uptake in adipocytes, increased synthesis of fatty acids and activation of lipoprotein lipase in adipose tissue (Eckel et al. 1979, Oben et al. 1991, Morgan 1996).”
Background
Research works printed but not linked: 3
- Elahi D, Meneilly GS, Minaker KL, Rowe JW & Andersen DK 1986 Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. In Proceedings of the Sixth International Conference on Gastrointestinal Hormones, Vancouver, BC, p 18. Ottawa: National Research Council of Canadian Research Journals.
- Flatt PR, Kwasowski P, Howland RJ & Bailey CJ 1991 Gastric inhibitory polypeptide and insulin responses to orally administered amino acids in genetically obese hyperglycaemic (ob/ob) mice. Journal of Nutrition 121 1123-1128.
- Schmidt WE, Siegel EG, Ebert R & Creutzfeldt W 1986 N-terminal tyrosine-alanine is required for the insulin releasing activity of glucose-dependent insulinotropic polypeptide. European Journal of Clinical Investigation 16 A9.
Cited by
Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor
Parthier, C., Kleinschmidt, M., Neumann, P., Rudolph, R., Manhart, S., Schlenzig, D., Fanghänel, J., Rahfeld, J.-U., Demuth, H.-U., & Stubbs, M. T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706404104 · Cited by 232
Gault, V. A., Irwin, N., Green, B. D., McCluskey, J. T., Greer, B., Bailey, C. J., Harriott, P., O’Harte, F. P. M., & Flatt, P. R. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2436 · Cited by 173
Self-citationChapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S., & Kim, S. (2009) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 171
Deacon, C. F., Danielsen, P., Klarskov, L., Olesen, M., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 145
“GIP receptors have been identified in several tissues (34,35), and there are reports that GIP promotes glucose uptake in muscle (36) and fat (37–39).”
BackgroundHinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H.-U., & McIntosh, C. H. S. (2002) · Diabetes · doi:10.2337/diabetes.51.3.652 · Cited by 131
Irwin, N., McClean, P. L., O'Harte, F. P. M., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0692-2 · Cited by 106
“In relation to this, GIP has been shown to inhibit gastric acid secretion [21], attenuate glucagon-stimulated glucose production [22], decrease hepatic insulin extraction [23] stimulate glucose uptake in muscle [24] and increase both fatty acid synthesis and lipoprotein lipase activity in adipocytes [25, 26].”
BackgroundSelf-citationGault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6364 · Cited by 108
Self-citationZarrinpar, A., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 103
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2003) · Neuropeptides · doi:10.1016/j.npep.2003.09.002 · Cited by 107
Self-citationGault, V. A., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01361-5 · Cited by 99
Self-citationProlonged unloading of rat soleus muscle causes distinct adaptations of the gene profile
Wittwer, M., Flück, M., Hoppeler, H., Müller, S., Desplanches, D., & Billeter, R. (2002) · The FASEB Journal · doi:10.1096/fj.01-0792fje · Cited by 91
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 82
O'Harte, F. P. M., Gault, V. A., Parker, J. C., Harriott, P., Mooney, M. H., Bailey, C. J., & Flatt, P. R. (2002) · Diabetologia · doi:10.1007/s00125-002-0894-6 · Cited by 73
“Moreover GIP has been proposed to exert various extrapancreatic effects, which could contribute to anthyperglycaemic activity in vivo including stimulation of peripheral glucose uptake [16, 53, 54, 55].”
BackgroundSelf-citationGIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women
Rudovich, N. N., Kaiser, S., Engeli, S., Osterhoff, M. A., Gögebakan, Ö., Blüher, M., & Pfeiffer, A. F. H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.006 · Cited by 74
O'Harte, F. P., Mooney, M. H., & Flatt, P. R. (1999) · Diabetes · doi:10.2337/diabetes.48.4.758 · Cited by 68
Self-citationBoyd, A. C., Abdel‐Wahab, Y. H. A., McKillop, A. M., McNulty, H., Barnett, C. R., O'Harte, F. P. M., & Flatt, P. R. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(00)00113-6 · Cited by 58
Self-citationMarenah, L., Flatt, P. R., Orr, D. F., Shaw, C., & Abdel‐Wahab, Y. H. A. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06293 · Cited by 54
Self-citationDoan, H. V., Riyajan, S., Iyara, R., & Chudapongse, N. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2328-0 · Cited by 57
Irwin, N., O'Harte, F. P. M., Gault, V. A., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., & Flatt, P. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0509997 · Cited by 52
Self-citationO'Harte, F., Mooney, M., Kelly, C., & Flatt, P. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650639 · Cited by 50
“Finally, other findings in our laboratory indicate that GIP has a potent effect on glucose uptake and metabolism in isolated mouse diaphragm muscle (O’Harte et al. 1998c).”
BackgroundMethodResultSelf-citationIrwin, N., Gault, V. A., Green, B. D., Greer, B., McCluskey, J. T., Harriott, P., O’Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.110 · Cited by 49
“For example, GIP is known to promote glucose uptake, glucose oxidation and glycogenesis in muscle tissue (O’Harte et al., 1998) and to stimulate glucose transport and increase fatty acid synthesis in adipocytes (Eckel et al.”
BackgroundSelf-citationO'Harte, F. P. M., Abdel‐Wahab, Y. H. A., Conlon, J. M., & Flatt, P. R. (1998) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(98)00084-1 · Cited by 42
Self-citationPleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Irwin, N., Clarke, G. C., Green, B. D., Greer, B., Harriott, P., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.013 · Cited by 40
Self-citationGAULT, V. A., FLATT, P. R., BAILEY, C. J., HARRIOTT, P., GREER, B., MOONEY, M. H., & O'HARTE, F. P. M. (2002) · Biochemical Journal · doi:10.1042/bj20020319 · Cited by 39
Self-citationGault, V., Flatt, P., Harriott, P., Mooney, M., Bailey, C., & O'Harte, F. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1760133 · Cited by 38
“Furthermore, NH2-terminal glucitol-GIP displayed markedly enhanced insulinotropic potency in clonal pancreatic -cells and improved in vivo biological activity in animals with type 2 diabetes (O’Harte et al. 1998b, 2000).”
BackgroundResultInfluentialSelf-citationMarenah, L., Flatt, P. R., Orr, D. F., McClean, S., Shaw, C., & Abdel‐Wahab, Y. H. A. (2004) · Biological Chemistry · doi:10.1515/bc.2004.027 · Cited by 42
Self-citationGault, V. A., Kerr, B. D., Irwin, N., & Flatt, P. R. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.03.011 · Cited by 36
Self-citationSite‐specific synthesis of Amadori‐modified peptides on solid phase
Frolov, A., Singer, D. L., & Hoffmann, R. (2005) · Journal of Peptide Science · doi:10.1002/psc.739 · Cited by 34
Frolov, A., & Hoffmann, R. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2377-1 · Cited by 25
Solid‐phase synthesis of glucose‐derived Amadori peptides
Frolov, A., Singer, D. L., & Hoffmann, R. (2007) · Journal of Peptide Science · doi:10.1002/psc.901 · Cited by 22
Structure, antihyperglycemic activity and cellular actions of a novel diglycated human insulin
O'Harte, F. P. M., Boyd, A., McKillop, A. M., Abdel‐Wahab, Y. H. A., McNulty, H., Barnett, C. R., Conlon, J. M., Højrup, P., & Flatt, P. R. (2000) · Peptides · doi:10.1016/s0196-9781(00)00306-5 · Cited by 23
Self-citationJepeal, L. I., Boylan, M. O., & Wolfe, M. M. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.01.024 · Cited by 25
“In the presence of elevated blood glucose, incretins stimulate insulin secretion from pancreatic β-cells (O’Harte et al., 1998; Usdin et al., 1993; Yip et al., 1998).”
BackgroundPhysiological endocrine control of energy homeostasis and postprandial blood glucose levels.
Gagliardino, J. J. (2005) · PubMed · Cited by 31
Irwin, N., Green, B. D., Gault, V. A., Cassidy, R. S., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2005) · Peptides · doi:10.1016/j.peptides.2005.08.003 · Cited by 21
“[29] O’Harte FPM, Gray AM, Flatt PR.”
BackgroundSelf-citationMcClean, P. L., Gault, V. A., Irwin, N., McCluskey, J. T., & Flatt, P. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00712.x · Cited by 19
Self-citationParker, J. C., Lavery, K. S., Irwin, N., Green, B., Greer, B., Harriott, P., O'Harte, F. P. M., Gault, V. A., & Flatt, P. R. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06904 · Cited by 18
Self-citationAbdel‐Wahab, Y. H. A., Marenah, L., Orr, D. F., Shaw, C., & Flatt, P. R. (2005) · Biological Chemistry · doi:10.1515/bc.2005.068 · Cited by 18
“This pattern of responsiveness shares certain similarities with the actions of GLP-1 and GIP in the b-cell.”
BackgroundSelf-citationDe Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Snook, L. A., Nelson, E. M., Dyck, D. J., Wright, D. C., & Holloway, G. P. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00003.2015 · Cited by 17
“In contrast to GLP-1, in addition to the current study, demonstrating a direct effect of GIP on glucose transport, GIP has been shown to increase glucose uptake in adipocytes (40), and in mice, GIP alone increases glucose transport into isolated abdominal muscle to the same degree as insulin (32).”
BackgroundResultInfluentialGault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00027-1 · Cited by 17
Self-citationGIP-Based Therapeutics for Diabetes and Obesity
Gault, V. A., Irwin, N., & Flatt, P. R. (2008) · Current Chemical Biology · doi:10.2174/187231308783334108 · Cited by 17
Self-citationLarsen, M. O., Rolin, B., Ribel, U., Wilken, M., Deacon, C. F., Svendsen, O., Gotfredsen, C. F., & Carr, R. D. (2003) · Journal of Diabetes Research · doi:10.1155/edr.2003.93 · Cited by 21
“GIP is one possibility, and the increased intact GIP levels found in the present study may have contributed to the effective uptake of glucose [44, 51, 52, 73].”
BackgroundIrwin, N., Green, B. D., Parker, J. C., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.03.006 · Cited by 15
Self-citationCharacterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists
Gault, V. A., Hunter, K., Irwin, N., Green, B. D., Greer, B., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.03.001 · Cited by 17
Self-citationGreen, B., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00455.x · Cited by 15
Self-citationNutrient regulation of pancreatic β-cell function in diabetes: problems and potential solutions
Flatt, P. R., & Green, B. D. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340774 · Cited by 14
Self-citationO'Harte, F. P. M., Hunter, K., Gault, V. A., Irwin, N., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2006 · Cited by 14
“Acute administration of (Pro(3))GIP with an intraperitoneal injection of glucose exacerbates glycemic and insulinotropic excursions thought to be due to both inhibition of the insulinotropic actions of high levels of endogenous GIP (14, 15) and blocking of other extrapancreatic glucose-lowering actions (31).”
BackgroundSelf-citationDeChristopher, L. R., & Tucker, K. L. (2024) · Nutrition Journal · doi:10.1186/s12937-024-00978-6 · Cited by 15
“…unpaired fructose, promotes gut in situ chemical modification (fructosylation) of partially digested dietary proteins and gut hormones (GLP1/ GIP), an overlooked source of atherogenic advanced glycation end-products (AGE), referred to as Fru-AGE [65–70], and gut hormone dysregulation [68, 70].”
BackgroundMarenah, L., Flatt, P. R., Orr, D. F., Shaw, C., & Abdel‐Wahab, Y. H. A. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.008 · Cited by 10
Self-citationDPIV — Natural Substrates of Medical Importance
Meester, I. D., Durinx, C., Proost, P., Scharpe, S., & Lambier, A. (2002) · Springer eBooks · doi:10.1007/978-1-4615-0619-5_9 · Cited by 8
Yang, G., Liang, X., Qin, C., Yang, L., Zhang, Y., Lu, R., Yan, X., Meng, X., & Nie, G. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737682 · Cited by 6
Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance
Craig, S. L., Gault, V. A., Hamscher, G., & Irwin, N. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0557 · Cited by 5
Chromatographic separation of glycated peptide isomers derived from glucose and fructose
Schmutzler, S., & Hoffmann, R. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04243-9 · Cited by 4
“However, RP-HPLC does not well separate Amadori and Heyns peptides, as the polar hexosamine modification does not contribute much to retention, which is mainly driven by hydrophobic interactions [8].”
BackgroundMooney, M. H., Abdel‐Wahab, Y. H. A., Morgan, L., O'Harte, F. P. M., & Flatt, P. R. (2001) · Endocrine · doi:10.1385/endo:16:3:167 · Cited by 6
Self-citationNew treatments for type 2 diabetes mellitus: combined therapy with sitagliptin
Gagliardino, J. J., Santoro, S., Arellano, S., & Girolamo, G. D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1495 · Cited by 4
“Interacting with these receptors, GIP inhibits hepatic glucose production [49] , glucose uptake by muscle [50] and glucose transport in adipose tissue [51] , fatty acid synthesis [52] , and lipoprotein lipase activity in adipose tissue [53] .”
BackgroundSharkey, S. J., Lafferty, R. A., Harnedy‐Rothwell, P. A., Gite, S., Whooley, J., Allsopp, P. J., Fitzgerald, R. J., & O'Harte, F. P. M. (2025) · ACS Food Science & Technology · doi:10.1021/acsfoodscitech.5c00135 · Cited by 2
Self-citationHinke, S. A., Pederson, R. A., & McIntosh, C. H. S. (2006) · Springer eBooks · doi:10.1007/0-387-32824-6_13 · Cited by 1
“glycated GIP in the stimulation of glucose uptake and oxidation, and glycogenesis in striated muscle strips [53], but when comparing insulinotropic activity using clonal insulin producing cells, the situation was reversed [54].”
BackgroundRole of gastrointestinal hormones in the metabolic dysfunction in obesity and associated diseases
Rudovich, N. N. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-7245
“8 role appears to be as an anabolic agent with a stimulatory effect on fat synthesis in adipocytes and glucose utilisation in muscle [10, 11, 14].”
BackgroundUtilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Metadata
- Authors
- O'Harte, F., Gray, A., & Flatt, P.
- Affiliations
- University of Ulster (GB)
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 1998-02-01
- Volume
- 156
- Issue
- 2
- Pages
- 237-243
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2152960998
- Cited by
- 60
- References
- 37
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2018: 1 · 2015: 1 · 2012: 1
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Aston University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucose-dependent insulinotropic polypeptide, glycation, glucose uptake, glucose oxidation, glycogen synthesis, muscle glycogen, lactic acid production, abdominal muscles, hyperglycemia, peptide modification, glucose metabolism
- MeSH terms
- Animals, Biological Transport, Gastric Inhibitory Polypeptide, Glucose, Glycogen, Glycosylation, Insulin, Male, Oxidation-Reduction, Stimulation, Chemical, Muscle, Skeletal, Lactic Acid, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.